{"title":"Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications.","authors":"Daohong Chen","doi":"10.34172/apb.43306","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>It tends not only to shed lights on an emerging classification framework of disease according to the shared molecular pathogenesis across various organs/tissues, but also to inspire more efficient paradigms of pharmaceutic innovation in a broader medical perspective.</p><p><strong>Methods: </strong>Literature review and re-thinking.</p><p><strong>Results: </strong>This article has sorted out an updated profile of the outstanding targeted medications with an extending list of clinical indications in oncology and beyond.</p><p><strong>Conclusion: </strong>Pharmaceutic development can be processed in a less risky and more affordable manner through drug repurpose or tissue agnostic approval.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"14 4","pages":"737-744"},"PeriodicalIF":3.1000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970494/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced pharmaceutical bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/apb.43306","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: It tends not only to shed lights on an emerging classification framework of disease according to the shared molecular pathogenesis across various organs/tissues, but also to inspire more efficient paradigms of pharmaceutic innovation in a broader medical perspective.
Methods: Literature review and re-thinking.
Results: This article has sorted out an updated profile of the outstanding targeted medications with an extending list of clinical indications in oncology and beyond.
Conclusion: Pharmaceutic development can be processed in a less risky and more affordable manner through drug repurpose or tissue agnostic approval.